Miltefosine enhances the fitness of a non-virulent drug-resistantLeishmania infantumstrain | Zendy

Eline Eberhardt | Zendy; Dimitri Bulté | Zendy; Lieselotte Van Bockstal | Zendy; Magali Van den Kerkhof | Zendy; Paul Cos | Zendy; Peter Delputte | Zendy; Sarah Hendrickx | Zendy; Louis Maes | Zendy; Guy Caljon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Miltefosine enhances the fitness of a non-virulent drug-resistantLeishmania infantumstrain

Author(s) -

Eline Eberhardt,

Dimitri Bulté,

Lieselotte Van Bockstal,

Magali Van den Kerkhof,

Paul Cos,

Peter Delputte,

Sarah Hendrickx,

Louis Maes,

Guy Caljon

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky450

Subject(s) - miltefosine , visceral leishmaniasis , biology , virulence , leishmaniasis , microbiology and biotechnology , in vivo , drug resistance , virology , infectivity , leishmania infantum , immunology , genetics , gene , virus

Miltefosine is currently the only oral drug for visceral leishmaniasis, and although deficiency in an aminophospholipid/miltefosine transporter (MT) is sufficient to elicit drug resistance, very few naturally miltefosine-resistant (MIL-R) strains have yet been isolated. This study aimed to make a detailed analysis of the impact of acquired miltefosine resistance and miltefosine treatment on in vivo infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research